Reviews of Behavioral, Social and Policy Prevention
é Sex-related
HIV risk reduction
¨ R Behavioral interventions to reduce risk for
sexual transmission of HIV among men who have sex with men
é Condom use
¨ P Structural and community-level interventions
for increasing condom use to prevent HIV and other sexually transmitted
infections.
¨ P Behavioral interventions for increasing condom
use in women with HIV
é Drug-related
HIV risk reduction
¨ Drug-related behavior change
¨ P Psychosocial interventions for the reduction
of injection and sexual risk behaviour for preventing HIV in drug users
é Interventions
targeting specific populations
¨ P Behavioral interventions for reducing HIV
infection in employees in occupational settings
¨ P Harm reduction interventions to prevent
HIV/AIDS transmission in involuntary detainees
¨ R Interventions for improving the psychosocial
wellbeing of children affected by HIV/AIDS.
¨ P Interventions
to modify sexual risk behaviours for preventing HIV in homeless youth
é Specific
types of interventions
¨ R Abstinence-only programs for HIV infection
prevention in high-income countries
¨ R Abstinence-plus programs for HIV infection
prevention in high-income countries
¨ R Home-based HIV voluntary counseling and
testing in developing countries
¨ P Interventions for reduction of stigma in
people with HIV/AIDS
¨ R Mass media interventions for promoting HIV
testing
¨ P Routine vs. voluntary HIV testing for
increasing HIV testing rates
¨ P School-based interventions to postpone sexual
intercourse and promote condom use among adolescents
¨
P Testing interventions for increasing uptake of HIV/AIDS services
Reviews of Biomedical Prevention
é Post-exposure
prophylaxis
¨ R Antiretroviral post-exposure prophylaxis (PEP)
for occupational HIV exposure
¨ P Effectiveness and safety of HIV post-exposure
prophylaxis after sexual, injecting-drug-use or other non-occupational
exposure.
é Pre-exposure
prophylaxis
¨ R Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals
é Prevention
of perinatal transmission
¨ R Antiretrovirals for reducing the risk of
mother-to-child transmission of HIV infection
¨ R Efficacy and safety of cesarean delivery for
prevention of mother-to-child transmission of HIV-1
¨ R Interventions for preventing late postnatal
mother-to-child transmission of HIV
¨ R Interventions for reducing the risk of
mother-to-child transmission of HIV infection
¨ R Vaginal
disinfection for preventing mother-to-child transmission of HIV infection
¨ R Vitamin A supplementation for reducing the
risk of mother-to-child transmission of HIV infection
é Condom
efficacy
¨ R Condom effectiveness in reducing heterosexual
HIV transmission
¨ P Female condom for preventing HIV and sexually
transmitted infections
é STI
treatment
¨ R Population-based interventions for reducing
sexually transmitted infections, including HIV infection
é Microbicides
¨ R Nonoxynol-9 for
preventing vaginal acquisition of HIV infection by women from men
é Circumcision
¨ R Male circumcision for prevention of heterosexual
acquisition of HIV in men
¨ P Male circumcision for prevention of homosexual
acquisition of HIV in men
é Vaccines
é Safety of
blood products
é Syringe and
needle use
Reviews of Therapeutics, Prognostics and Diagnostics
é Antiretrovirals,
including protease inhibitors
¨ Combination therapy
¨ P A combination drug of
abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDS
¨ R Antiretroviral regimens for patients with HIV
who fail first-line antiretroviral therapy
¨ P Efavirenz versus nevirapine as a
non-nucleoside reverse transcriptase inhibitor in initial combination
antiretroviral therapy for HIV infection
¨ P Effectiveness and safety of first-line
fixed-dose TNF + EMC + EFZ for patients with HIV
¨ P Ritonavir-boosted protease
inhibitor-containing regimens versus non-boosted protease-inhibitor-containing
regimens for reducing morbidity and mortality in people with HIV/AIDS
¨ R Stavudine, lamivudine and nevirapine
combination therapy for treatment of HIV infection and AIDS in adults.
¨ R Three- or four- versus two-drug antiretroviral
maintenance regimens for HIV infection
¨ Single drugs
¨ R Immediate versus deferred zidovudine (AZT) in
asymptomatic or mildly symptomatic HIV infected adults
¨ R Zidovudine (AZT) versus AZT plus didanosine
(ddI) versus AZT plus zalcitabine (ddC) in HIV
infected adults
¨ Structured treatment interruptions
¨ R Structured treatment interruptions (STI) in
chronic suppressed HIV infection in adults
¨ R Structured treatment interruptions (STI) in
chronic unsuppressed HIV infection in adults
¨ HIV+ children
¨
P Antiretroviral therapy for HIV-infected infants
é Prophylaxis
and treatment of opportunistic infections (OIs)
¨ Prophylaxis
¨ R Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection
¨ R Antifungal interventions for the primary
prevention of cryptococcal disease in adults with HIV
¨ R Cotrimoxazole for prophylaxis or treatment of
opportunistic infections of HIV/AIDS in patients with previous history of
hypersensitivity to cotrimoxazole
¨ R Cotrimoxazole prophylaxis for opportunistic
infections in adults with HIV
¨ R Cotrimoxazole prophylaxis for opportunistic
infections in children with HIV infection
¨ R Impact of tuberculosis preventive therapy on
tuberculosis and mortality in HIV-infected children
¨ P Interventions for the prevention of
mycobacterium avium complex in adults and children
with HIV
¨ R Management of toxoplasmic encephalitis in
HIV-infected adults (with an emphasis on resource-poor settings)
¨ TB
¨ P Duration of therapy for tuberculosis in
patients infected with Human Immunodeficiency Virus
¨ R Treatment of latent tuberculosis infection in
HIV infected persons
¨ Oropharyngeal infections
¨ R Interventions for the prevention and
management of oropharyngeal candidiasis associated with HIV infection in adults
and children
¨ Cryptosporidiosis
¨ R Prevention and treatment of cryptosporidiosis
in immunocompromised patients
é Treatment
of Malignancies
¨ R Interventions for Previously Untreated
Patients with AIDS-Associated Non Hodgkin´s Lymphoma
¨ R Interventions for squamous
cell carcinoma of the conjunctiva in HIV-infected individuals
¨ R Interventions for treating AIDS-associated Hodgkin´s lymphoma in treatment-naive adults
¨ P Treatment for leiomyosarcoma
and leiomyoma in children with HIV infection
¨ R Treatment of Kaposi's sarcoma in HIV-1
infected individuals with emphasis on resource poor settings
é Immunizations
¨ P Measles/MMR
vaccine for infants born to HIV-positive mothers
¨ P Pneumococcal
vaccine for prevention of Streptococcus pneumoniae infection in HIV infected
persons.
é Prognostics
Markers
¨ P Antiretroviral resistance testing in
treatment-naive HIV-infected adults
¨ P Genotypic antiretroviral resistance testing at
viral failure in people with HIV
¨ R Therapeutic drug monitoring of antiretrovirals
for people with HIV
é Diagnostics
Assays
é Complementary
Medicine
¨ R Herbal medicines for treating HIV infection
and AIDS
¨ P The medical use of cannabis for reducing
morbidity and mortality in patients with HIV/AIDS
é Treatment
of other conditions
¨ R Adjunctive therapies for AIDS dementia complex
¨ R Antimotility agents
for chronic diarrhoea in people with HIV/AIDS
¨ P Antiviral agents for treating CMV infection of
the nervous system in people with HIV
¨ P Deworming helminth co-infected individuals for delaying HIV disease progression
¨ R The effects of antiviral therapy of genital
herpes in HIV-infected individuals
¨
R Treatment for anemia in people with AIDS
¨
R Treatment of acute cryptococcal meningitis in
HIV infected adults, with an emphasis on resource-limited settings
Reviews of Health Services and Care
é Health care
characteristics
¨ R Interventions for educating traditional
healers about STD and HIV medicine
¨ P Provider training and experience for people
living with HIV/AIDS
¨ R Setting and organization of care for persons
living with HIV/AIDS
é Quality of
life
¨ R Aerobic exercise interventions for adults
living with HIV/AIDS
¨ R Anabolic steroids for the treatment of weight
loss in HIV-infected individuals
¨ P Cognitive behavioural therapy (CBT) for adults
with HIV
¨ R Family support in reducing morbidity and
mortality in HIV-infected persons
¨ P Home-based care for reducing morbidity and
mortality in people infected with HIV/AIDS
¨ R Iron supplementation for reducing morbidity
and mortality in children with HIV
¨ P Massage therapy for people with HIV/AIDS
¨ R Micronutrient supplementation in children and
adults with HIV infection
¨ R Nutritional interventions for reducing
morbidity and mortality in people with HIV
¨ R Progressive resistive exercise interventions
for adults living with HIV/AIDS
é Treatment
adherence
¨ R Patient support and education for promoting
adherence to highly active antiretroviral therapy for HIV/AIDS
¨ P Substitution of nurses for doctors in managing
HIV/AIDS antiretroviral therapy
REGISTERED TITLES